Claudia Crippa

Brescia, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Early identification of functional high-risk multiple myeloma patients after transplant: the predictive power of fat fraction and Response Assessment Category score in diffusion-weighted whole-body magnetic resonance imaging.

Early identification of functional high-risk multiple myeloma patients after transplant: the predictive power of fat fraction and Response Assessment Category score in diffusion-weighted whole-body magnetic resonance imaging.

Journal: Haematologica
Published: January 19, 2025

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation.

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation.

Journal: Hematological oncology
Published: December 09, 2024

What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?

What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?

Journal: Haematologica
Published: June 12, 2023

Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma.

Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma.

Journal: American journal of hematology
Published: April 02, 2023

Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.

Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.

Journal: Cancer medicine
Published: May 22, 2021

Skip pattern approach toward the early access of innovative anticancer drugs.

Skip pattern approach toward the early access of innovative anticancer drugs.

Journal: ESMO open
Published: April 22, 2021

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.

Journal: Leukemia
Published: February 14, 2021

The novel Mechanical Ventilator Milano for the COVID-19 pandemic.

The novel Mechanical Ventilator Milano for the COVID-19 pandemic.

Journal: Physics of fluids (Woodbury, N.Y. : 1994)
Published: January 16, 2021

Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.

Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.

Journal: Hematological oncology
Published: August 11, 2020

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.

Journal: The Lancet. Haematology
Published: April 09, 2020

Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.

Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.

Journal: American journal of hematology
Published: March 01, 2020

Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.

Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.

Journal: British journal of haematology
Published: July 04, 2019
Showing 1-12 of 20

Last Updated: 09/26/2026